Bora Pharmaceuticals (保瑞藥業) has officially inaugurated the expansion of its Tanvex BioPharma (泰福-KY) facility in San Diego, marking a transition into a high-growth phase powered by dual "small and large molecule" engines. Chairman Bobby Sheng noted that 2026 will be a defining year for Bora as it deepens its global supply chain footprint.

Key Strategic Pillars:

• CDMO Momentum: Bora’s CDMO arm has secured contract renewals with major global pharma clients. The Board recently approved capital increases for the Maple Grove, MN facility, positioning the group to capture long-term supply chain shifts as global players domesticate production under the US Biosecure Act.
• Product Pipeline: Over 10 new products are slated for US launch this year. Notably, Upsher-Smith (USL) recently received FDA approval for Cyclosporine Ophthalmic Emulsion 0.05%. USL’s specialized pediatric epilepsy portfolio also saw an 85% YoY market share increase in 2025.
• Biologics Expansion: The US$30 million San Diego upgrade adds two 2,000L single-use bioreactors, bringing total capacity to 9,000L. This allows Tanvex BioPharma to offer "one-stop" services from late-stage clinical trials to commercial production.
• The Third Engine: Subsidiary SunWay Biotech (晨暉) recently secured Taiwan patents for its SWM-008 Red Yeast Rice for NAFLD and weight management. The facility is undergoing final GMP validation to enter the nutraceutical CDMO market via a partnership with Weider.

Resource: 保瑞雙引擎熱轉，2026年三箭齊發營運重啟成長